查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433551

异位性皮肤炎临床试验市场规模、份额、趋势分析报告：按分子类型、试验设计、试验阶段、地区和细分市场预测，2024-2030

Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report By Molecule Type (Small molecules, Large Molecules), By Study Designs, By Study Phase, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

异位性皮肤炎临床试验市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球异位性皮肤炎临床试验市场预计将达到48.4亿美元，2024年至2030年复合年增长率为11.1%。

生物技术和医学的研究开拓、异位性皮肤炎盛行率的增加、製药公司对开发新药的投资增加、CRO 和赞助公司之间的合作和收购的增加、临床研究的技术进步和异位性皮肤炎。皮肤炎产品管道的增加、全球化临床试验等是预测期内支持全球市场良好成长的一些因素。

创新和轻鬆进入诊所是製药公司的重要因素。此外，製药和生物製药公司越来越注重开发新药。例如，美国FDA表示，几种治疗异位性皮肤炎的潜在疗法将在未来几年内推向市场。可能进入市场的生物製药包括协和麒麟的locatinlimab、礼来的lebrikizumab、KeyMed Bioscience的CM310和Astra Zeneca的tozolakimab。因此，治疗药物管道的增加是增加市场成长的主要因素之一。

此外，异位性皮肤炎的盛行率不断上升是推动市场成长的关键催化剂。异位性皮肤炎是一种慢性发炎皮肤病，在全球范围内患病率显着增加，影响所有年龄层的患者。根据《2022 年全球疾病负担 (GBD)》报告，到 2022 年，大约 2.23 亿人将患有异位性皮肤炎。其中 1 至 4 岁年龄层有 4,300 万人。盛行率的快速增加迫切需要更有效、更有针对性的治疗方案。因此，製药公司、研究机构和医疗机构正在增加对临床试验的投资，以探索新的治疗性介入。

此外，一些公司正专注于併购等无机策略倡议，以增强其在产业中的地位。例如，2022年3月，辉瑞宣布收购Arena Pharmaceuticals，这是一家临床阶段的公司，致力于开发针对包括异位性皮肤炎在内的多种发炎疾病的创新潜在治疗方法。

异位性皮肤炎临床试验市场报告亮点

  • 由于越来越多的生技药品正在渗透到异位性皮肤炎临床试验产业，到2023年，大分子将在分子类型上占据压倒性的份额，达到53.2%。
  • 由于大量采用介入试验设计的临床试验，介入试验在市场上占据主导地位。
  • III期预计将在2023年占据最高的市场占有率。这是由于正在进行 III 期试验的药物数量不断增加。此外，III期试验的成本远高于其他阶段，占了最大的市场占有率。
  • 由于该地区异位性皮肤炎盛行率不断上升、该地区主要市场参与者的存在、政府对优质医疗保健的支持以及报销计划的可用性等因素，北美在市场上占据主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 异位性皮肤炎临床试验市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 异位性皮肤炎临床试验市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 异位性皮肤炎临床试验市场：依分子类型估算及趋势分析

  • 2023 年和 2030 年分子类型市场占有率
  • 细分仪表板
  • 按分子类型分類的全球异位性皮肤炎临床试验市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第五章 异位性皮肤炎临床试验市场：透过研究设计进行估算与趋势分析

  • 2023 年和 2030 年按研究设计分類的市场占有率
  • 细分仪表板
  • 按研究设计分類的全球异位性皮肤炎临床试验市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第六章 异位性皮肤炎临床试验市场：分阶段估计与趋势分析

  • 2023 年及 2030 年分阶段市场占有率
  • 细分仪表板
  • 全球异位性皮肤炎临床试验市场分阶段展望
  • 2018年至2030年市场规模、预测与趋势分析

第七章 异位性皮肤炎临床试验市场：区域估计与趋势分析

  • 2023 年及 2030 年按地区分類的市场占有率分析
  • 按地区分類的市场仪表板
  • 区域市场简介
  • 2018年至2030年市场规模、预测与趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争形势

  • 公司/竞争对手分类
    • 创新者
    • 市场领导者
    • 新兴企业
    • 2023 年公司市场占有率分析
  • 公司简介
    • Charles River Laboratories
    • Imavita
    • REPROCELL Inc.
    • Oncodesign services
    • BIOCYTOGEN
    • QIMA LTD
    • Novotech
    • Redoxis
    • Syneos Health
    • Hooke Laboratories, LLC
Product Code: GVR-4-68040-182-6

Atopic Dermatitis Clinical Trials Market Growth & Trends:

The global atopic dermatitis clinical trials market is expected to reach USD 4.84 billion by 2030 and expand at a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advancements in biotechnology and medicine, growing prevalence of atopic dermatitis, increasing investments by pharmaceutical companies in the development of novel drugs, rising partnerships and acquisitions among CROs and sponsor companies, technological advancements in clinical research, growing pipeline of atopic dermatitis products, and globalization of clinical trials are few of the factors supporting the lucrative growth of the global market during the forecast period.

For pharmaceutical companies, innovation and easy access to clinics are critical factors. Furthermore, pharmaceutical and biopharmaceutical companies increasingly focus on developing novel drugs for treating atopic dermatitis. For instance, the U.S. FDA stated that several potential therapeutics will be launched in the coming years to treat atopic dermatitis. A few of the potential biologics likely to enter the market include Rocatinlimab by -Kyowa Kirin Co., Ltd., lebrikizumab by Eli Lilly and Company, CM310 by Keymed Biosciences, tozorakimab by AstraZeneca and several others. Hence, the increasing pipeline of therapeutics is one of the major factors augmenting market growth.

Furthermore, the increasing prevalence of atopic dermatitis is a significant catalyst propelling the market growth. Atopic dermatitis is a chronic inflammatory skin condition that has witnessed a notable rise in incidence globally, affecting individuals of all ages. In 2022, approximately 223 million individuals are coping with atopic dermatitis, per the Global Burden of Disease (GBD) 2022 report. Among them, approximately 43 million falls within the age group of 1 to 4 years. This surge in prevalence has created a compelling need for more effective and targeted treatment options. As a result, pharmaceutical companies, research institutions, and healthcare organizations are increasingly investing in clinical trials to explore novel therapeutic interventions.

Moreover, several companies are focusing on inorganic strategic initiatives such as mergers and acquisitions to enhance their position in the industry. For instance, in March 2022, Pfizer Inc. announced the acquisition of Arena Pharmaceuticals, a clinical-stage company dedicated to developing innovative potential therapies for various immuno-inflammatory diseases, including atopic dermatitis.

Atopic Dermatitis Clinical Trials Market Report Highlights:

  • Large molecules dominated the molecule type segment with a 53.2% share in 2023 due to the increasing pipeline of biologics penetrating the atopic dermatitis clinical trials industry.
  • Interventional trials dominated the market owing to the large number of clinical trials with interventional study designs.
  • Phase III category by phase segment is anticipated to hold the highest market share in 2023. This is due to the increasing number of drugs undergoing phase III studies. Moreover, the cost of phase III studies is much higher than the other phases, contributing to the largest market share.
  • North America dominated the market owing to factors such as increasing the prevalence of atopic dermatitis in the region, presence of major market players in the region, government support for quality healthcare, and availability of reimbursement.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Approach 1: Commodity flow approach
    • 1.8.3. Parent Market Analysis (Model 2)
    • 1.8.4. Approach 2: Parent Market Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of atopic dermatitis
      • 3.2.1.2. Growing pipeline of therapeutics
      • 3.2.1.3. Increasing funding and investments
    • 3.2.2. market restraint analysis
      • 3.2.2.1. High cost of clinical trials
      • 3.2.2.2. Issues in patient recruitment and retention
  • 3.3. Atopic Dermatitis Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Clinical Trials Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Molecule Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Atopic Dermatitis Clinical Trials Market by Molecule Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Small molecules
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Large Molecules
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Clinical Trials Market: Study Designs Estimates & Trend Analysis

  • 5.1. Study Designs Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Atopic Dermatitis Clinical Trials Market by Study Designs Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Interventional
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Observational
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. Phase Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Atopic Dermatitis Clinical Trials Market by Phase Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Phase I
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Phase II
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Phase III
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Phase IV
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Thailand
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Charles River Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Imavita
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. REPROCELL Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Oncodesign services
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. BIOCYTOGEN
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. QIMA LTD
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Novotech
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Redoxis
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Syneos Health
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Hooke Laboratories, LLC
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 4 North America Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 5 North America Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 6 U.S. Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 8 U.S. Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 9 Canada Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 10 Canada Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 11 Canada Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 12 Europe Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 14 Europe Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 15 Europe Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 16 UK Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 17 UK Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 18 UK Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 19 Germany Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 20 Germany Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 21 Germany Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 22 France Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 23 France Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 24 France Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 25 Italy Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 26 Italy Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 27 Italy Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 28 Spain Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 29 Spain Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 30 Spain Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 31 Denmark Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 33 Denmark Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 34 Sweden Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 36 Sweden Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 37 Norway Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 38 Norway Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 39 Norway Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 44 Japan Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 45 Japan Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 46 Japan Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 47 China Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 48 China Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 49 China Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 50 India Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 51 India Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 52 India Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 53 Australia Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 54 Australia Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 55 Australia Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 56 Thailand Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 57 Thailand Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 58 Thailand Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 59 South Korea Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 61 South Korea Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 62 Latin America Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 65 Latin America Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 68 Brazil Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 69 Mexico Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 71 Mexico Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 72 Argentina Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 74 Argentina Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 75 MEA Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 77 MEA Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 78 MEA Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 79 South Africa Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 81 South Africa Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 85 UAE Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 86 UAE Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 87 UAE Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Atopic Dermatitis Clinical Trials market: market outlook
  • Fig. 14 Atopic Dermatitis Clinical Trials competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Atopic Dermatitis Clinical Trials market driver impact
  • Fig. 20 Atopic Dermatitis Clinical Trials market restraint impact
  • Fig. 21 Atopic Dermatitis Clinical Trials market: Molecule Type movement analysis
  • Fig. 22 Atopic Dermatitis Clinical Trials market: Molecule Type outlook and key takeaways
  • Fig. 23 Small molecules market estimates and forecast, 2018 - 2030
  • Fig. 24 Large Molecules market estimates and forecast, 2018 - 2030
  • Fig. 25 Atopic Dermatitis Clinical Trials Market: Study Designs movement Analysis
  • Fig. 26 Atopic Dermatitis Clinical Trials market: Study Designs outlook and key takeaways
  • Fig. 27 Interventional market estimates and forecasts,2018 - 2030
  • Fig. 28 Observational market estimates and forecasts,2018 - 2030
  • Fig. 29 Atopic Dermatitis Clinical Trials Market: Phase movement Analysis
  • Fig. 30 Atopic Dermatitis Clinical Trials market: Phase outlook and key takeaways
  • Fig. 31 Phase I market estimates and forecasts,2018 - 2030
  • Fig. 32 Phase II market estimates and forecasts,2018 - 2030
  • Fig. 33 Phase III market estimates and forecasts,2018 - 2030
  • Fig. 34 Phase IV market estimates and forecasts,2018 - 2030
  • Fig. 35 Global Atopic Dermatitis Clinical Trials market: Regional movement analysis
  • Fig. 36 Global Atopic Dermatitis Clinical Trials market: Regional outlook and key takeaways
  • Fig. 37 Global Atopic Dermatitis Clinical Trials market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America
  • Fig. 45 North America market estimates and forecasts, 2018 - 2030
  • Fig. 46 U.S.
  • Fig. 47 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 48 Canada
  • Fig. 49 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 56 France
  • Fig. 57 France market estimates and forecasts, 2018 - 2030
  • Fig. 58 Italy
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 60 Spain
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 62 Denmark
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 64 Sweden
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 66 Norway
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 68 Asia Pacific
  • Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 70 Japan
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 72 China
  • Fig. 73 China market estimates and forecasts, 2018 - 2030
  • Fig. 74 India
  • Fig. 75 India market estimates and forecasts, 2018 - 2030
  • Fig. 76 Australia
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 78 Thailand
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 80 South Korea
  • Fig. 81 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 82 Latin America
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 84 Brazil
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 86 Mexico
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 88 Argentina
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 90 Middle East and Africa
  • Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Africa
  • Fig. 93 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 Saudi Arabia
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 96 UAE
  • Fig. 97 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 98 Kuwait
  • Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 100 Market share of key market players- Atopic Dermatitis Clinical Trials market